RBC Capital Maintains Outperform on Opus Genetics, Raises Price Target to $11
HC Wainwright & Co. Maintains Buy on Opus Genetics, Raises Price Target to $14
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
Opus Genetics Q3 EPS $(0.46) Misses $(0.15) Estimate, Sales $1.137M Miss $1.959M Estimate
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis
Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Opus Genetics Presents Clinical Findings From OPGx-BEST1 And OPGx-LCA5 Gene Therapy Programs At Retina In Rio 2026; Phase 3 Clinical Trial Dosing For OPGx-LCA5 Expected In Q4 Of 2026
Opus Genetics to Present at the Chardan Annual Healthcare Conference
Jones Trading Maintains Buy on Opus Genetics, Raises Price Target to $17
Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - Slideshow
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
Opus Genetics: A Resounding Study Success Merits A Higher Valuation
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.